开云app官网登录入口网页版-官方正版

#百时美施贵宝#

35篇内容 | 1732人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1353504, encodeId=90bb1353504ce, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=肥厚型心肌病患者新选择！联拓生物合作伙伴百时美施贵宝公司的Camzyos (mavacamten) 获美国FDA批准, objectType=article, longId=725731, objectId=7110e25731dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7110e25731dc, replyNumber=0, likeNumber=78, createdTime=2022-04-30, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7110e25731dc, moduleTitle=肥厚型心肌病患者新选择！联拓生物合作伙伴百时美施贵宝公司的Camzyos (mavacamten) 获美国FDA批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7110e25731dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353503, encodeId=20eb1353503b8, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=221346, objectId=ab662213469b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab662213469b, replyNumber=0, likeNumber=122, createdTime=2021-12-02, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab662213469b, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ab662213469b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353502, encodeId=6e411353502a0, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=卫材与百时美施贵宝在ADC药物达成或高达30亿美元战略合作协议, objectType=article, longId=212888, objectId=cecd21288851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cecd21288851, replyNumber=0, likeNumber=103, createdTime=2021-06-20, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cecd21288851, moduleTitle=卫材与百时美施贵宝在ADC药物达成或高达30亿美元战略合作协议, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cecd21288851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353499, encodeId=3cc51353499d2, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝与Agenus签署15.6亿美元协议，获得AGEN1777全球**授权, objectType=article, longId=211532, objectId=14ab21153250, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14ab21153250, replyNumber=0, likeNumber=78, createdTime=2021-05-20, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14ab21153250, moduleTitle=百时美施贵宝与Agenus签署15.6亿美元协议，获得AGEN1777全球**授权, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=14ab21153250)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353500, encodeId=ab2d1353500c4, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果, objectType=article, longId=210709, objectId=659b210e098a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=659b210e098a, replyNumber=0, likeNumber=59, createdTime=2021-05-02, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=659b210e098a, moduleTitle=百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=659b210e098a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353501, encodeId=2e851353501fd, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, objectType=article, longId=210359, objectId=837e210359f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=837e210359f2, replyNumber=0, likeNumber=123, createdTime=2021-04-25, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=837e210359f2, moduleTitle=百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=837e210359f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353498, encodeId=60e5135349839, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝血液病创新药Luspatercept上市申请获CDE优先审评, objectType=article, longId=206759, objectId=7050206e59ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7050206e59ba, replyNumber=0, likeNumber=97, createdTime=2021-02-05, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7050206e59ba, moduleTitle=百时美施贵宝血液病创新药Luspatercept上市申请获CDE优先审评, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7050206e59ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353497, encodeId=b4d2135349e73, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝斥131亿美元收购心血管药物研发商 , objectType=article, longId=201808, objectId=854e201808dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=854e201808dc, replyNumber=0, likeNumber=64, createdTime=2020-10-09, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=854e201808dc, moduleTitle=百时美施贵宝斥131亿美元收购心血管药物研发商 , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=854e201808dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353496, encodeId=a5e81353496bd, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=194250, objectId=8f001942503c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f001942503c, replyNumber=0, likeNumber=103, createdTime=2020-05-18, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f001942503c, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8f001942503c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353495, encodeId=beba1353495fe, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝宣布CheckMate870临床研究达到主要研究终点，未发现新的安全性信号, objectType=article, longId=194191, objectId=15161941913d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15161941913d, replyNumber=0, likeNumber=80, createdTime=2020-05-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15161941913d, moduleTitle=百时美施贵宝宣布CheckMate870临床研究达到主要研究终点，未发现新的安全性信号, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=15161941913d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353494, encodeId=081d1353494dd, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝宣布，美国与欧洲监管机构已接受欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于肺癌一线治疗的申请, objectType=article, longId=191924, objectId=e2a4191924a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2a4191924a2, replyNumber=0, likeNumber=99, createdTime=2020-04-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2a4191924a2, moduleTitle=百时美施贵宝宣布，美国与欧洲监管机构已接受欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于肺癌一线治疗的申请, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e2a4191924a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353493, encodeId=0fbb1353493ed, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝的1-磷酸鞘氨醇受体调节剂ozanimod，获FDA批准治疗复发型多发性硬化症, objectType=article, longId=190924, objectId=13da19092498, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13da19092498, replyNumber=0, likeNumber=110, createdTime=2020-03-28, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13da19092498, moduleTitle=百时美施贵宝的1-磷酸鞘氨醇受体调节剂ozanimod，获FDA批准治疗复发型多发性硬化症, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=13da19092498)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353492, encodeId=dce3135349270, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败, objectType=article, longId=188481, objectId=680d18848160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=680d18848160, replyNumber=0, likeNumber=60, createdTime=2020-02-22, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=680d18848160, moduleTitle=百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=680d18848160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353491, encodeId=b72913534919f, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可, objectType=article, longId=184956, objectId=2ccf1849567a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ccf1849567a, replyNumber=0, likeNumber=69, createdTime=2019-12-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ccf1849567a, moduleTitle=百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2ccf1849567a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353490, encodeId=2754135349001, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, objectType=article, longId=184904, objectId=574418490463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=574418490463, replyNumber=0, likeNumber=0, createdTime=2019-12-19, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=574418490463, moduleTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=574418490463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353489, encodeId=8e831353489c9, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, objectType=article, longId=184397, objectId=4dad18439e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dad18439e2a, replyNumber=0, likeNumber=67, createdTime=2019-12-09, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dad18439e2a, moduleTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4dad18439e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353488, encodeId=1c21135348873, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝公布CheckMate 227最终临床结果，数据喜人！, objectType=article, longId=180267, objectId=e3f218026ef1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3f218026ef1, replyNumber=0, likeNumber=67, createdTime=2019-10-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3f218026ef1, moduleTitle=百时美施贵宝公布CheckMate 227最终临床结果，数据喜人！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e3f218026ef1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353487, encodeId=8862135348ed0, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝公布欧狄沃®（nivolumab，纳武利尤单抗注射液）用于晚期经治非小细胞肺癌患者汇总五年总生存（OS）数据, objectType=article, longId=179251, objectId=fc171e9251bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc171e9251bb, replyNumber=0, likeNumber=63, createdTime=2019-09-12, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc171e9251bb, moduleTitle=百时美施贵宝公布欧狄沃®（nivolumab，纳武利尤单抗注射液）用于晚期经治非小细胞肺癌患者汇总五年总生存（OS）数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fc171e9251bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353486, encodeId=650213534865e, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, objectType=article, longId=176189, objectId=bfbc1e6189e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfbc1e6189e0, replyNumber=0, likeNumber=73, createdTime=2019-07-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfbc1e6189e0, moduleTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bfbc1e6189e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353485, encodeId=6b1f135348563, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果, objectType=article, longId=167618, objectId=e3fc16e61813, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3fc16e61813, replyNumber=0, likeNumber=101, createdTime=2019-06-05, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3fc16e61813, moduleTitle=2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e3fc16e61813)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

百时美施贵宝

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

肥厚型心肌病患者新选择！联拓生物合作伙伴百时美施贵宝公司的Camzyos (mavacamten) 获美国FDA批准

2022-04-30

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2021-12-02

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

卫材与百时美施贵宝在ADC药物达成或高达30亿美元战略合作协议

2021-06-20

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝与Agenus签署15.6亿美元协议，获得AGEN1777全球**授权

2021-05-20

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝公布了III期临床研究CheckMate -227第1部分随访结果

2021-05-02

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝公布III期临床研究CheckMate -9LA两年随访数据，结果喜人！

2021-04-25

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝血液病创新药Luspatercept上市申请获CDE优先审评

2021-02-05

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝斥131亿美元收购心血管药物研发商

2020-10-09

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2020-05-18

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝宣布CheckMate870临床研究达到主要研究终点，未发现新的安全性信号

2020-05-17

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝宣布，美国与欧洲监管机构已接受欧狄沃（纳武利尤单抗）联合伊匹木单抗及有限疗程化疗用于肺癌一线治疗的申请

2020-04-11

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝的1-磷酸鞘氨醇受体调节剂ozanimod，获FDA批准治疗复发型多发性硬化症

2020-03-28

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝的PD-1单抗Opdivo组合针对晚期胰腺癌的临床试验失败

2020-02-22

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝宣布向FDA申请其CAR-T细胞疗法liso-cel的许可

2019-12-21

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿

2019-12-19

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果

2019-12-09

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝公布CheckMate 227最终临床结果，数据喜人！

2019-10-01

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝公布欧狄沃®（nivolumab，纳武利尤单抗注射液）用于晚期经治非小细胞肺癌患者汇总五年总生存（OS）数据

2019-09-12

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点

2019-07-27

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

2019 ASCO：百时美施贵宝首次发布纳武利尤单抗联合伊匹木单抗治疗晚期肝细胞癌的临床研究结果

2019-06-05

科室
- - 订阅+
  - 更多科室
工具
服务